Literature DB >> 11781314

Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis.

Kari Anne Risan Tobin1, Stine M Ulven, Gertrud U Schuster, Hilde Hermansen Steineger, Sissel Mahle Andresen, Jan-Ake Gustafsson, Hilde Irene Nebb.   

Abstract

The nuclear receptor liver X receptor (LXR) alpha, an important regulator of cholesterol and bile acid metabolism, was analyzed after insulin stimulation in liver in vitro and in vivo. A time- and dose-dependent increase in LXRalpha steady-state mRNA level was seen after insulin stimulation of primary rat hepatocytes in culture. A maximal induction of 10-fold was obtained when hepatocytes were exposed to 400 nm insulin for 24 h. Cycloheximide, a potent inhibitor of protein synthesis, prevented induction of LXRalpha mRNA expression by insulin, indicating that the induction is dependent on de novo synthesis of proteins. Stabilization studies using actinomycin D indicated that insulin stimulation increased the half-life of LXRalpha transcripts in cultured primary hepatocytes. Complementary studies where rats and mice were injected with insulin induced LXRalpha mRNA levels and confirmed our in vitro studies. Furthermore, deletion of both the LXRalpha and LXRbeta genes (double knockout) in mice markedly suppressed insulin-mediated induction of an entire class of enzymes involved in both fatty acid and cholesterol metabolism. The discovery of insulin regulation of LXR in hepatic tissue as well as gene targeting studies in mice provide strong evidence that LXRs plays a central role not only in cholesterol homeostasis, but also in fatty acid metabolism. Furthermore, LXRs appear to be important insulin-mediating factors in regulation of lipogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781314     DOI: 10.1074/jbc.M109771200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c.

Authors:  Fabienne Foufelle; Pascal Ferré
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity.

Authors:  Christian Bindesbøll; Qiong Fan; Rikke C Nørgaard; Laura MacPherson; Hai-Bin Ruan; Jing Wu; Thomas Å Pedersen; Knut R Steffensen; Xiaoyong Yang; Jason Matthews; Susanne Mandrup; Hilde I Nebb; Line M Grønning-Wang
Journal:  J Lipid Res       Date:  2015-02-27       Impact factor: 5.922

Review 3.  Signalling mechanisms linking hepatic glucose and lipid metabolism.

Authors:  M O Weickert; A F H Pfeiffer
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

4.  Can the liver X receptor work its magic in skeletal muscle too?

Authors:  A Krook
Journal:  Diabetologia       Date:  2006-05       Impact factor: 10.122

Review 5.  Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health.

Authors:  Kristin M Hirahatake; Richard S Bruno; Bradley W Bolling; Christopher Blesso; Lacy M Alexander; Sean H Adams
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

Review 6.  Liver X receptors as therapeutic targets in metabolism and atherosclerosis.

Authors:  Takashi Nomiyama; Dennis Bruemmer
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

7.  Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes.

Authors:  Yan Liu; Haiyan Lin; Lin Jiang; Qingsen Shang; Lei Yin; Jiandie D Lin; Wen-Shu Wu; Liangyou Rui
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

8.  Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.

Authors:  Sushant Bhatnagar; Holly A Damron; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

9.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

10.  Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.

Authors:  Amena Archer; Nicolas Venteclef; Agneta Mode; Matteo Pedrelli; Chiara Gabbi; Karine Clément; Paolo Parini; Jan-Åke Gustafsson; Marion Korach-André
Journal:  Mol Endocrinol       Date:  2012-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.